{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T20:29:42Z","timestamp":1779136182121,"version":"3.51.4"},"reference-count":124,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Tumor growth and metastasis are reliant on intricate interactions between the host immune system and various counter-regulatory immune escape mechanisms employed by the tumor. Tumors can resist immune surveillance by modifying the expression of human leukocyte antigen (HLA) molecules, which results in the impaired presentation of tumor-associated antigens, subsequently evading detection and destruction by the immune system. The management of chronic lymphocytic leukemia (CLL) is based on symptom severity and includes various types of targeted therapies, including rituximab, obinutuzumab, ibrutinib, acalabrutinib, zanubrutinib, idelalisib, and venetoclax. These therapies rely on the recognition of specific peptides presented by HLAs on the surface of tumor cells by T cells, leading to an immune response. HLA class I molecules are found in most human cell types and interact with T-cell receptors (TCRs) to activate T cells, which play a vital role in inducing adaptive immune responses. However, tumor cells may evade T-cell attack by downregulating HLA expression, limiting the efficacy of HLA-dependent immunotherapy. The prognosis of CLL largely depends on the presence or absence of genetic abnormalities, such as del(17p), TP53 point mutations, and IGHV somatic hypermutation status. These oral targeted therapies alone or in combination with anti-CD20 antibodies have replaced chemoimmunotherapy as the primary treatment for CLL. In this review, we summarize the current clinical evidence on the impact of HLA- and cytokine-type responses on outcomes after targeted therapies currently used to treat CLL.<\/jats:p>","DOI":"10.3390\/jcm12072731","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T03:59:55Z","timestamp":1680753595000},"page":"2731","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessment of Impact of Human Leukocyte Antigen-Type and Cytokine-Type Responses on Outcomes after Targeted Therapy Currently Used to Treat Chronic Lymphocytic Leukemia"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0532-7929","authenticated-orcid":false,"given":"Mihaela","family":"Andreescu","sequence":"first","affiliation":[{"name":"Department of Clinical Sciences, Hematology, Faculty of Medicine, Titu Maiorescu University of Bucharest, 040051 Bucharest, Romania"},{"name":"Department of Hematology, Colentina Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoleta","family":"Berbec","sequence":"additional","affiliation":[{"name":"Department of Hematology, Coltea Clinical Hospital, 020125 Bucharest, Romania"},{"name":"Faculty of Medicine, Carol Davila University of Bucharest, 040051 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3075-499X","authenticated-orcid":false,"given":"Alina","family":"Tanase","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Carol Davila University of Bucharest, 040051 Bucharest, Romania"},{"name":"Department of Hematology, Fundeni Clinical Hospital, 020125 Bucharest, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.imlet.2019.03.004","article-title":"Interactions between cancer stem cells, immune system and some environmental components: Friends or foes?","volume":"208","author":"Vahidian","year":"2019","journal-title":"Immunol. Lett."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1158\/1078-0432.CCR-14-1860","article-title":"Immune escape mechanisms as a guide for cancer ImmunotherapyTailoring cancer immunotherapy","volume":"21","author":"Beatty","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"106700","DOI":"10.1016\/j.intimp.2020.106700","article-title":"Mechanisms of immune escape in the cancer immune cycle","volume":"86","author":"Tang","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3389\/fonc.2020.01290","article-title":"Mechanisms of cancer resistance to immunotherapy","volume":"10","author":"Bai","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41586-019-1593-5","article-title":"Harnessing innate immunity in cancer therapy","volume":"574","author":"Demaria","year":"2019","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.coi.2021.03.014","article-title":"Conformational sensing of major histocompatibility complex (MHC) class I molecules by immune receptors and intracellular assembly factors","volume":"70","author":"Geng","year":"2021","journal-title":"Curr. Opin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1053\/j.seminoncol.2016.02.009","article-title":"Prognostic factors and risk stratification in chronic lymphocytic leukemia","volume":"43","author":"Parikh","year":"2016","journal-title":"Semin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1016\/S2352-3026(19)30085-7","article-title":"Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: A retrospective, pooled cohort study with external validations","volume":"6","author":"Soumerai","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/bjh.16042","article-title":"Association of gene mutations with time-to-first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients","volume":"187","author":"Hu","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.acr.2019.03.002","article-title":"From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy","volume":"143","author":"Osipov","year":"2019","journal-title":"Adv. Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Mhibik, M., Wiestner, A., and Sun, C. (2019). Harnessing the effects of BTKi on T cells for effective immunotherapy against CLL. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21010068"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1080\/10245332.2015.1101965","article-title":"Increased regulatory T cells in acute lymphoblastic leukaemia patients","volume":"21","author":"Idris","year":"2016","journal-title":"Hematology"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Allegra, A., Musolino, C., Tonacci, A., Pioggia, G., Casciaro, M., and Gangemi, S. (2020). Clinico-Biological Implications of Modified Levels of Cytokines in Chronic Lymphocytic Leukemia: A Possible Therapeutic Role. Cancers, 12.","DOI":"10.3390\/cancers12020524"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Ghamlouch, H., Ouled-Haddou, H., Damaj, G., Royer, B., Gubler, B., and Marolleau, J.-P. (2013). A combination of cytokines rescues highly purified leukemic CLL B-cells from spontaneous apoptosis in vitro. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0060370"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Bagnara, D., Mazzarello, A.N., Ghiotto, F., Colombo, M., Cutrona, G., Fais, F., and Ferrarini, M. (2022). Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232214249"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2905","DOI":"10.3389\/fimmu.2018.02905","article-title":"Anti-cancer therapies employing IL-2 cytokine tumor targeting: Contribution of innate, adaptive and immunosuppressive cells in the anti-tumor efficacy","volume":"9","author":"Mortara","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e002189","DOI":"10.1136\/jitc-2020-002189","article-title":"Expanded antigen-experienced CD160+ CD8+ effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia","volume":"9","author":"Bozorgmehr","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e1353856","DOI":"10.1080\/2162402X.2017.1353856","article-title":"Ig-like transcript 2 (ILT2) suppresses T cell function in chronic lymphocytic leukemia","volume":"6","author":"Payer","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"166667","DOI":"10.1016\/j.jmb.2020.10.002","article-title":"The alternate pathway for BCR signaling induced by IL-4 requires Lyn tyrosine kinase","volume":"433","author":"Khan","year":"2021","journal-title":"J. Mol. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"670","DOI":"10.4049\/jimmunol.1203211","article-title":"IL-4 upregulates Ig\u03b1 and Ig\u03b2 protein, resulting in augmented IgM maturation and B cell receptor\u2013triggered B cell activation","volume":"191","author":"Guo","year":"2013","journal-title":"J. Immunol."},{"key":"ref_21","first-page":"3015","article-title":"IL-4 enhances expression and function of surface IgM in CLL cells","volume":"127","author":"Blunt","year":"2016","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0145-2126(96)00053-7","article-title":"Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients","volume":"21","author":"Frankfurt","year":"1997","journal-title":"Leuk. Res."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Ruiz-Lafuente, N., Alcaraz-Garcia, M.-J., Sebastian-Ruiz, S., Garcia-Serna, A.-M., Gomez-Espuch, J., Moraleda, J.-M., Minguela, A., Garcia-Alonso, A.-M., and Parrado, A. (2015). IL-4 up-regulates MiR-21 and the MiRNAs hosted in the CLCN5 gene in chronic lymphocytic leukemia. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0124936"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/bloodadvances.2017015560","article-title":"CD40L\/IL-4\u2013stimulated CLL demonstrates variation in translational regulation of DNA damage response genes including ATM","volume":"2","author":"Lezina","year":"2018","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","article-title":"Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer","volume":"15","author":"Johnson","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Arruga, F., Gyau, B.B., Iannello, A., Vitale, N., Vaisitti, T., and Deaglio, S. (2020). Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051825"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12964-020-00538-5","article-title":"IL-9 and IL-9-producing cells in tumor immunity","volume":"18","author":"Wan","year":"2020","journal-title":"Cell Commun. Signal."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s12288-017-0804-1","article-title":"Evaluation of Interleukin-9 Expression as a Potential Therapeutic Target in Chronic Lymphocytic Leukemia in a Cohort of Egyptian Patients","volume":"33","author":"Abbassy","year":"2017","journal-title":"Indian J. Hematol. Blood Transfus."},{"key":"ref_29","first-page":"716","article-title":"Role of high expression of IL-9 in prognosis of CLL","volume":"7","author":"Chen","year":"2014","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"11315","DOI":"10.1038\/s41598-017-11803-y","article-title":"IL-4 enhances IL-10 production in Th1 cells: Implications for Th1 and Th2 regulation","volume":"7","author":"Mitchell","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0304-3835(01)00868-0","article-title":"Factor (s) released from irradiated B-CLL cells induce apoptosis in leukemic lymphocytes","volume":"179","author":"Bessler","year":"2002","journal-title":"Cancer Lett."},{"key":"ref_32","first-page":"256","article-title":"Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: Correlation with phenotypic characteristics and outcome","volume":"97","author":"Fayad","year":"2001","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_33","first-page":"224","article-title":"Modulation of apoptosis by cytokines in B-cell chronic lymphocytic leukemia","volume":"38","author":"Castejon","year":"1999","journal-title":"Cytom. J. Int. Soc. Anal. Cytol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.intimp.2016.07.008","article-title":"Increased IL-10\/IL-17 ratio is aggravated along with the prognosis of patients with chronic lymphocytic leukemia","volume":"40","author":"Pang","year":"2016","journal-title":"Int. Immunopharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5771","DOI":"10.4049\/jimmunol.180.9.5771","article-title":"IL-10: The master regulator of immunity to infection","volume":"180","author":"Couper","year":"2008","journal-title":"J. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1146\/annurev-immunol-020711-074934","article-title":"Immune regulatory function of B cells","volume":"30","author":"Mauri","year":"2012","journal-title":"Annu. Rev. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/leu.2012.165","article-title":"Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function","volume":"27","author":"DiLillo","year":"2013","journal-title":"Leukemia"},{"key":"ref_38","first-page":"4384","article-title":"Classification of lymphoid neoplasms: The microscope as a tool for disease discovery","volume":"112","author":"Jaffe","year":"2008","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"4180","DOI":"10.4049\/jimmunol.1800241","article-title":"Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity","volume":"200","author":"Alhakeem","year":"2018","journal-title":"J. Immunol."},{"key":"ref_40","first-page":"1615","article-title":"Alteration of IFN-\u03b3, IL-4, IL-17 and TGF-\u03b2 levels in serum of patients with chronic lymphocytic leukemia treated with FCR","volume":"25","author":"Chen","year":"2017","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/leu.2011.12","article-title":"IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells","volume":"25","author":"Coscia","year":"2011","journal-title":"Leukemia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood.V76.2.393.bloodjournal762393","article-title":"Production of tumor necrosis factor-alpha by B-cell chronic lymphocytic leukemia cells: A possible regulatory role of TNF in the progression of the disease","volume":"76","author":"Foa","year":"1990","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"13994","DOI":"10.1002\/jcp.28086","article-title":"Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia","volume":"234","author":"Wang","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_44","first-page":"83","article-title":"Interleukin-2 prevents programmed cell death in chronic lymphocytic leukemia cells","volume":"58","author":"Huang","year":"1993","journal-title":"Int. J. Hematol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1007\/s13277-012-0628-4","article-title":"Downregulation of IL-17-producing T cells is associated with regulatory T cell expansion and disease progression in chronic lymphocytic leukemia","volume":"34","author":"Ghalamfarsa","year":"2013","journal-title":"Tumour Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.bbmt.2017.04.023","article-title":"IFN-\u03b1 is effective for treatment of minimal residual disease in patients with acute leukemia after allogeneic hematopoietic stem cell transplantation: Results of a registry study","volume":"23","author":"Mo","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"De Cecco, L., Capaia, M., Zupo, S., Cutrona, G., Matis, S., Brizzolara, A., Orengo, A.M., Croce, M., Marchesi, E., and Ferrarini, M. (2015). Interleukin 21 Controls mRNA and MicroRNA Expression in CD40-Activated Chronic Lymphocytic Leukemia Cells. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134706"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1593\/tlo.10172","article-title":"Interleukin 22 signaling promotes cell growth in mantle cell lymphoma","volume":"4","author":"Gelebart","year":"2011","journal-title":"Transl. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"eaal1571","DOI":"10.1126\/scitranslmed.aal1571","article-title":"Microenvironmental regulation of the IL-23R\/IL-23 axis overrides chronic lymphocytic leukemia indolence","volume":"10","author":"Cutrona","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1182\/blood-2003-07-2500","article-title":"Down-regulation of HLA-A and HLA-Bw6, but not HLA-Bw4, allospecificities in leukemic cells: An escape mechanism from CTL and NK attack?","volume":"103","author":"Demanet","year":"2004","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00262-008-0601-7","article-title":"Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells","volume":"58","author":"Verheyden","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00262-016-1806-9","article-title":"Killer-cell immunoglobulin-like receptor genes and ligands and their role in hematologic malignancies","volume":"65","author":"Varbanova","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e1330235","DOI":"10.1080\/2162402X.2017.1330235","article-title":"NK cell dysfunction in chronic lymphocytic leukemia is associated with loss of the mature cells expressing inhibitory killer cell Ig-like receptors","volume":"6","author":"MacFarlane","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Yano, M., Byrd, J.C., and Muthusamy, N. (2022). Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential. Cancers, 14.","DOI":"10.3390\/cancers14235787"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/j.1365-2567.2011.03521.x","article-title":"Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemia","volume":"135","author":"Costello","year":"2012","journal-title":"Immunology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00251-010-0494-4","article-title":"Frequent loss of heterozygosity in the \u03b22-microglobulin region of chromosome 15 in primary human tumors","volume":"63","author":"Maleno","year":"2011","journal-title":"Immunogenetics"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/1759-7714.12252","article-title":"Loss of heterozygosity at the human leukocyte antigen locus in thymic epithelial tumors","volume":"6","author":"Chen","year":"2015","journal-title":"Thorac. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1365-2141.2004.05151.x","article-title":"Loss of heterozygosity, a frequent but a non-exclusive mechanism responsible for HLA dysregulation in non-Hodgkin\u2019s lymphomas","volume":"127","author":"Tilanus","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.humimm.2019.02.009","article-title":"Pretransplant HLA typing revealed loss of heterozygosity in the major histocompatibility complex in a patient with acute myeloid leukemia","volume":"80","author":"Lobashevsky","year":"2019","journal-title":"Hum. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5104","DOI":"10.3389\/fimmu.2022.944872","article-title":"Individual HLA heterogeneity and its implications for cellular immune evasion in cancer and beyond","volume":"13","author":"Pagliuca","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.humimm.2022.08.002","article-title":"HLA homozygosity is associated with Non-Hodgkin lymphoma","volume":"83","author":"Roark","year":"2022","journal-title":"Hum. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2141.2011.08706.x","article-title":"Common genetic variation at 15q25. 2 impacts on chronic lymphocytic leukaemia risk","volume":"154","author":"Jamroziak","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/leu.2011.30","article-title":"HLA homozygosity and haplotype bias among patients with chronic lymphocytic leukemia: Implications for disease control by physiological immune surveillance","volume":"25","author":"Shah","year":"2011","journal-title":"Leukemia"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3389\/fimmu.2016.00653","article-title":"Hla-G-mediated immune tolerance: Past and new outlooks","volume":"7","author":"Gregori","year":"2016","journal-title":"Front. Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3389\/fimmu.2020.01178","article-title":"HLA-G genotype\/expression\/disease association studies: Success, hurdles, and perspectives","volume":"11","author":"Amodio","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"744324","DOI":"10.3389\/fimmu.2021.744324","article-title":"HLA-G: An Important Mediator of Maternal-Fetal Immune-Tolerance","volume":"12","author":"Zhuang","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.3389\/fimmu.2020.01685","article-title":"HLA-G neo-expression on tumors","volume":"11","author":"Loustau","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"581","DOI":"10.21608\/ejhm.2020.88564","article-title":"Prognostic Value of Soluble HLA-G and CD38 Expression in Patients with Chronic Lymphocytic Leukemia in Egypt","volume":"80","author":"Thabet","year":"2020","journal-title":"Egypt. J. Hosp. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"587","DOI":"10.21608\/ejhm.2020.88567","article-title":"Expression of Tolerogenic HLA-G Confer Worse Outcome in Patients with Chronic Lymphocytic Leukemia","volume":"80","author":"Thabet","year":"2020","journal-title":"Egypt. J. Hosp. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"608614","DOI":"10.3389\/fimmu.2020.608614","article-title":"Inhibition of iNKT cells by the HLA-G-ILT2 checkpoint and poor stimulation by HLA-G-expressing tolerogenic DC","volume":"11","author":"Wu","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00018-022-04359-2","article-title":"The HLA-G immune checkpoint: A new immuno-stimulatory role for the \u03b11-domain-deleted isoform","volume":"79","author":"Daouya","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Krijgsman, D., Roelands, J., Hendrickx, W., Bedognetti, D., and Kuppen, P.J. (2020). HLA-G: A new immune checkpoint in cancer?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21124528"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.canlet.2011.07.019","article-title":"Human leukocyte antigen-G in cancer: Are they clinically relevant?","volume":"311","author":"Yan","year":"2011","journal-title":"Cancer Lett."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.cytogfr.2014.04.004","article-title":"The emerging role of soluble HLA-G in the control of chemotaxis","volume":"25","author":"Morandi","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s00018-010-0584-3","article-title":"Emerging topics and new perspectives on HLA-G","volume":"68","author":"Fainardi","year":"2011","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"548","DOI":"10.3324\/haematol.2014.113803","article-title":"HLA-G expression levels influence the tolerogenic activity of human DC-10","volume":"100","author":"Amodio","year":"2015","journal-title":"Haematologica"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.4049\/jimmunol.1300438","article-title":"Binding of HLA-G to ITIM-bearing Ig-like transcript 2 receptor suppresses B cell responses","volume":"192","author":"Naji","year":"2014","journal-title":"J. Immunol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"17957","DOI":"10.1073\/pnas.1221535110","article-title":"Exocytosis acts as a modulator of the ILT4-mediated inhibition of neutrophil functions","volume":"110","author":"Baudhuin","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.humimm.2008.08.280","article-title":"HLA-G-dependent suppressor cells: Diverse by nature, function, and significance","volume":"69","author":"Carosella","year":"2008","journal-title":"Hum. Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/eji.200425741","article-title":"Tolerization of dendritic cells by HLA-G","volume":"35","author":"Ristich","year":"2005","journal-title":"Eur. J. Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1182\/blood-2009-07-234872","article-title":"Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4\/HLA-G pathway","volume":"116","author":"Gregori","year":"2010","journal-title":"Blood"},{"key":"ref_83","first-page":"112","article-title":"Long-term outcomes for ibrutinib\u2013rituximab and chemoimmunotherapy in CLL: Updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/JBM.S190784","article-title":"How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin\u2019s lymphomas","volume":"10","author":"Mohammed","year":"2019","journal-title":"J. Blood Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2019-126824","article-title":"Ibrutinib and rituximab provides superior clinical outcome compared to FCR in younger patients with chronic lymphocytic leukemia (CLL): Extended follow-up from the E1912 trial","volume":"134","author":"Shanafelt","year":"2019","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1053\/j.seminoncol.2014.08.006","article-title":"Postulated Mechanisms of Resistance of B-Cell Non-Hodgkin Lymphoma to Rituximab Treatment Regimens: Strategies to Overcome Resistance","volume":"41","author":"Bonavida","year":"2014","journal-title":"Semin. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.leukres.2005.09.008","article-title":"Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines","volume":"30","author":"Takei","year":"2006","journal-title":"Leuk. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1158\/1078-0432.CCR-07-1255","article-title":"Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression","volume":"14","author":"Olejniczak","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1158\/1078-0432.CCR-08-1403","article-title":"Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin\u2019s lymphoma","volume":"15","author":"Terui","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1182\/blood-2008-08-175208","article-title":"Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: Its prevalence and clinical significance","volume":"113","author":"Hiraga","year":"2009","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood.V98.12.3383","article-title":"CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: Further regulation by CD55 and CD59","volume":"98","author":"Golay","year":"2001","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.4049\/jimmunol.1300187","article-title":"Recombinant human IL-15 trans-presentation by B leukemic cells from chronic lymphocytic leukemia induces autologous NK cell proliferation leading to improved anti-CD20 immunotherapy","volume":"191","author":"Laprevotte","year":"2013","journal-title":"J. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.exphem.2011.08.006","article-title":"Interleukin-15 enhances rituximab-dependent cytotoxicity against chronic lymphocytic leukemia cells and overcomes transforming growth factor beta-mediated immunosuppression","volume":"39","author":"Moga","year":"2011","journal-title":"Exp. Hematol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1084\/jem.179.3.999","article-title":"Transforming growth factor beta as endogenous growth inhibitor of chronic lymphocytic leukemia B cells","volume":"179","author":"Lotz","year":"1994","journal-title":"J. Exp. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1006\/cimm.1997.1132","article-title":"IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: The potential role of NK cell subpopulations","volume":"179","author":"Evans","year":"1997","journal-title":"Cell. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1002\/cncr.26091","article-title":"Nonmyeloablative allogeneic stem cell transplantation in relapsed\/refractory chronic lymphocytic leukemia: Long-term follow-up, prognostic factors, and effect of human leukocyte histocompatibility antigen subtype on outcome","volume":"117","author":"Khouri","year":"2011","journal-title":"Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1080\/13543784.2018.1482273","article-title":"Targeting the B cell receptor pathway in non-Hodgkin lymphoma","volume":"27","author":"Valla","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Dammeijer","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nature11309","article-title":"Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling","volume":"489","author":"Schneider","year":"2012","journal-title":"Nature"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e1512455","DOI":"10.1080\/2162402X.2018.1512455","article-title":"Ibrutinib significantly inhibited Bruton\u2019s tyrosine kinase (BTK) phosphorylation, in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model","volume":"8","author":"Chu","year":"2019","journal-title":"Oncoimmunology"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"George, B., Chowdhury, S.M., Hart, A., Sircar, A., Singh, S.K., Nath, U.K., Mamgain, M., Singhal, N.K., Sehgal, L., and Jain, N. (2020). Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas. Cancers, 12.","DOI":"10.3390\/cancers12051328"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1056\/NEJMoa1400029","article-title":"Resistance mechanisms for the Bruton\u2019s tyrosine kinase inhibitor ibrutinib","volume":"370","author":"Woyach","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/17474086.2018.1435268","article-title":"Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?","volume":"11","author":"Lampson","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/blood-2017-01-761726","article-title":"Acquired mutations associated with ibrutinib resistance in Waldenstr\u00f6m macroglobulinemia","volume":"129","author":"Xu","year":"2017","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1056\/NEJMc1402716","article-title":"Ibrutinib resistance in chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1158\/1078-0432.CCR-15-2921","article-title":"Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia","volume":"23","author":"Amin","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/cncr.31831","article-title":"Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation","volume":"125","author":"Jain","year":"2019","journal-title":"Cancer"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"11589","DOI":"10.1038\/ncomms11589","article-title":"Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition","volume":"7","author":"Burger","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"68833","DOI":"10.18632\/oncotarget.11932","article-title":"Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL","volume":"7","author":"Sharma","year":"2016","journal-title":"Oncotarget"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.leukres.2018.08.006","article-title":"Dynamic changes in HLA-DR expression during short-term and long-term ibrutinib treatment in patients with chronic lymphocytic leukemia","volume":"72","author":"Manukyan","year":"2018","journal-title":"Leuk. Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e432","DOI":"10.1016\/j.clml.2020.12.016","article-title":"Retrospective Analysis of the Impact of Adverse Event\u2013Triggered Idelalisib Interruption and Dose Reduction on Clinical Outcomes in Patients with Relapsed\/Refractory B-Cell Malignancies","volume":"21","author":"Ma","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1182\/blood-2021-153982","article-title":"Comparing the PI3K Inhibitors in Hematological Malignancies: Review of Faers","volume":"138","author":"Ramadas","year":"2021","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1182\/blood.2018881029","article-title":"IGF1R as druggable target mediating PI3K-\u03b4 inhibitor resistance in a murine model of chronic lymphocytic leukemia","volume":"134","author":"Scheffold","year":"2019","journal-title":"Blood"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood.2020006765","article-title":"Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia","volume":"138","author":"Murali","year":"2021","journal-title":"Blood"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/leu.2016.202","article-title":"Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia","volume":"31","author":"Eldfors","year":"2017","journal-title":"Leukemia"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","article-title":"P110\u03b1-mediated constitutive PI3K signaling limits the efficacy of p110\u03b4-selective inhibition in mantle cell lymphoma, particularly with multiple relapse","volume":"121","author":"Iyengar","year":"2013","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Lasica, M., and Anderson, M.A. (2021). Review of venetoclax in CLL, AML and multiple myeloma. J. Pers. Med., 11.","DOI":"10.3390\/jpm11060463"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood.2019002841","article-title":"How I manage CLL with venetoclax-based treatments","volume":"135","author":"Wierda","year":"2020","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1080\/10428194.2017.1283032","article-title":"Pathways and mechanisms of venetoclax resistance","volume":"58","author":"Bose","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s13045-018-0608-2","article-title":"BCL-2 as therapeutic target for hematological malignancies","volume":"11","author":"Perini","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41467-018-03170-7","article-title":"Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia","volume":"9","author":"Herling","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1186\/s12935-020-01614-z","article-title":"Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies","volume":"20","author":"Yue","year":"2020","journal-title":"Cancer Cell Int."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1182\/blood-2019-123410","article-title":"Combined Ibrutinib and Venetoclax Changes Myeloid Phenotype and Improves Immune Function in CLL Patients","volume":"134","author":"Svanberg","year":"2019","journal-title":"Blood"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/7\/2731\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:10:58Z","timestamp":1760123458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/7\/2731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":124,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["jcm12072731"],"URL":"https:\/\/doi.org\/10.3390\/jcm12072731","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]}}}